Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
UK buys 100,000 doses of GSK's experimental Covid drug
The treatment has yet to be approved by UK regulators but has been given the green light in the US, the EU and Japan
By
Hannah Boland
9 October 2021 • 7:00pm
Order value is $2.1bn
I thought it was separate deals but am not to certain, the government wants them distributing & may be employing the army to do so, in Britain they’ve called in the army to distribute fuel in emergencies.
GlaxoSmithKline LLC, Durham, North Carolina, was awarded a $279,862,800 firm-fixed-price contract for procurement, storage, and distribution of GlaxoSmithKline's monoclonal antibody therapeutic treatment Sotrovimab. Bids were solicited via the internet with one received. Work will be performed in Durham, North Carolina, with an estimated completion date of May 19, 2022. Fiscal 2021 Defense Production Act purchases, defense funds in the amount of $279,862,800 were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity (W58P05-21-C-0008). (Awarded Sept. 29, 2021)
Oct 8 (Reuters) - The U.S. Food and Drug Administration said on Friday distribution of GlaxoSmithKline GSK and Vir Biotechnology's VIR antibody treatment for COVID-19 would be controlled by the government.
The drug was authorized by the FDA in May but no supply deal was signed at the time with the U.S. government, which is already distributing rival treatments by Regeneron Pharmaceuticals Inc REGN and Eli Lilly LLY. nL3N2ND4CG
It was not clear whether a contract had been signed between the government and GSK/Vir. The U.S. Department of Health and Human Services did not immediately respond to Reuters' request for comment.
Biden has said he intends to increase orders for monoclonal antibody treatments, cited 70%, out product Sotrovimab has 85% efficacy.
There is only Regeneron & GSK/Vir with the availability to meet this demand.
GSK Seeks Approval for COVID-19 Drug in Japan
News
from Japan
Economy Sep 6, 2021
Read in other languages
English ??? ??? ??? Français Español ??????? ???????
Tokyo, Sept. 6 (Jiji Press)--British pharmaceutical company GlaxoSmithKline PLC said Monday it filed for Japanese government approval the same day for its COVID-19 drug to treat patients with mild to moderate symptoms
Michnaz, there are multiple approvals worldwide and multiple authorisations pending, Australia, America, UAE s and many others using Sotrovimab with outstanding success, take UAE they used it on 13,000 in a month with 100% success.
Europe has taken delivery and is distributing it, Brazil & India are about to approve in the next week.
I’d assume the U.K. will be soon.
To my knowledge there hasn’t been a single case of any major side effects.
The only resistance so far has been because it’s administered intravenously which is time & labour intensive, the trials to make it a straightforward intramuscular jab are about to conclude, if successful it’s a major game changer and currently in America for example they are preparing to make drive through centres should it become a jab.
Glaxo has a 8% stake.
https://www.fool.com/investing/2021/09/02/now-may-be-the-big-moment-for-these-2-covid-stocks/
Cheers TR64, now up 43% in a month, you were being criticised that Vir were down 40%, but that’s the life of bio-tech stocks.
Vir has the potential to be a 10bagger over the next few years, Hep b, HIV, Flu to name a few in late stage clinical trials.
Strong demand is growing for the monoclonal antibody that has been developed by Vir/GSK, the company have trademarked the treatment which was originally known as Vir7831, then Sotrovimab and will now be known as XEVUDY.
GSK have a joint collaboration deal for the treatment and also have a 8% stake in Vir.
The drug got full marketing authority in Australia today.
Glaxo own about 8% of Vir.
https://www.google.com/amp/s/www.fool.com/amp/investing/2021/08/09/3-vaccine-stocks-for-the-next-decade/
TR64, ditto, the funny thing is I was quite heavily in Aston Martin which is AML, so I thought you were telling me to stick to Aston Martin’s thread??.
Yeah 7832 is is supposed to be variant proof,also being tested as a vaccine and is administered intramuscularly is due to release results is due to release results soon, remember that the trials of 7831 ended early due to ‘profound efficacy’, now that would be a game changer!
A good red as well??
Cheers, we’re on the same wavelengths over Vir, I honestly believe it could end up a massive growth story, £4.5bn mkt cap, heavyweight partners, and exciting pipeline, the hepatitis b is the one £450m people worldwide have it and the trials so far have been really promising.
TR64, I am not disputing anything about Vir I have been a buyer for well over a year, all I was pointing out is Sotrovimab is now under the GSK brand and that’s better for Vir as they have a worldwide network already established to get to the end user.
The Mail article wasn’t about Vir, it was about the monoclonal antibodies in general, but mentioned GSK & Sotrovimab.
You still didn’t explain your AML remark, which came across as a bit rude, enlighten me.